poisar

Stocks · News reference

BTIG Maintains Buy on Intuitive Surgical, Lowers Price Target to $454

BenzingaBenzinga Newsdesk

BTIG analyst Ryan Zimmerman maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and lowers the price target from $469 to $454.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolBrendan Coffey

    Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

    Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.